Checkpoint Therapeutics Approves Merger with Sun Pharma

The latest update is out from Checkpoint Therapeutics ( (CKPT) ).

On May 28, 2025, Checkpoint Therapeutics held a virtual special meeting where stockholders approved the merger with Sun Pharmaceutical Industries. The merger will result in Checkpoint becoming a wholly owned subsidiary of Sun Pharma, with the merger expected to close around May 30, 2025. Additionally, stockholders approved a compensation proposal related to executive payments in connection with the merger, while an adjournment proposal was rendered unnecessary due to the approval of the merger proposal.

The most recent analyst rating on (CKPT) stock is a Hold with a $4.10 price target. To see the full list of analyst forecasts on Checkpoint Therapeutics stock, see the CKPT Stock Forecast page.

Spark’s Take on CKPT Stock

According to Spark, TipRanks’ AI Analyst, CKPT is a Neutral.

Checkpoint Therapeutics faces significant financial challenges with declining revenues and negative margins. However, the technical analysis shows strong upward momentum, and the recent merger agreement with Sun Pharma provides a positive outlook. The valuation remains unattractive due to the negative P/E ratio. Overall, while there are short-term opportunities, substantial financial issues pose long-term risks.

To see Spark’s full report on CKPT stock, click here.

More about Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a Delaware-based company operating in the pharmaceutical industry. It focuses on developing and commercializing targeted therapies for oncology, aiming to address unmet medical needs in cancer treatment.

Average Trading Volume: 3,036,487

Technical Sentiment Signal: Buy

Current Market Cap: $364.6M

Find detailed analytics on CKPT stock on TipRanks’ Stock Analysis page.